Upcoming topical TRPV1 anti-pruritic compounds.
Dermatol Online J
; 26(9)2020 Sep 15.
Article
em En
| MEDLINE
| ID: mdl-33054935
ABSTRACT
Transient receptor potential vanilloid type 1 (TRPV1) is found on sensory neurons, keratinocytes, sebocytes, and dendritic cells. Activated TRPV1 channels are believed to help propagate the itch sensation. Therefore, there has been great interest in targeting TRPV1 to treat pruritus. Since oral formulations aimed at TRPV1 have led to adverse effects such as hyperthermia, there has been emphasis on developing novel topical agents. Several companies are investigating topical TRPV1 anti-pruritic compounds and the initial data has been very promising. These drugs have the potential to be important treatment options for the management of itch. This paper reviews topical products in current development for pruritus that target TRPV1 channels.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Prurido
/
Canais de Cátion TRPV
/
Antipruriginosos
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article